Medicare Pilot Program Expands Coverage for CBD Products
Medicare has introduced a groundbreaking pilot program that includes coverage for specific cannabis products, aiming to increase senior citizens’ access to alternatives in the nearly $30 billion hemp industry. This initiative is part of broader governmental efforts to revise marijuana regulations, as highlighted by Health Secretary Robert F. Kennedy Jr., an advocate for non-traditional medical treatments.
Edo Banach, co-chair at Foley Hoag law firm, recognizes public dissatisfaction with existing chronic pain management methods. Under this Medicare program, healthcare providers can receive up to $500 annually per patient for discussing or providing certain CBD products. Initially, providers must cover the costs, as patients are not allowed to purchase the products directly.
The CBD products eligible under the program must have a delta-9 THC content under 0.3% or a maximum of 3 milligrams of THC per serving. They must also undergo third-party testing and meet state and local regulatory compliance requirements. Notably, patients with certain conditions like substance use disorder and COPD are excluded from this program.
Although medical marijuana is legal in most states, and recreational use is permitted in about half, federal law still prohibits marijuana. The proposal to reschedule marijuana does not equate to total legalization. FDA Commissioner Marty Makary recently stated that no bans will be enforced on oral CBD products covered by Medicare’s program.
The program's goal is to guide seniors who use cannabis for pain management without professional advice, mitigating risks of drug interactions and incorrect dosing. Leigh Vinocur from the National Compassionate Care Council stressed the importance of establishing clearer guidelines for these patients.
CMS Administrator Mehmet Oz noted that the pilot will offer valuable insights into CBD's practical application in healthcare settings. Despite opposition and lawsuits from anti-cannabis organizations citing health concerns for seniors, the program proceeds. Edo Banach cautioned that requiring providers to initially shoulder costs might limit participation, potentially impacting the pilot's success.
Anticipated legal changes in November could redefine hemp’s legal status, affecting substances legalized by Congress in 2018. CMS plans to adjust the limits on hemp products in the program to align with these forthcoming regulatory changes.